BTAI — BioXcel Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $43.96m
- $116.91m
- $2.27m
Annual cashflow statement for BioXcel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -82.2 | -107 | -166 | -179 | -59.6 |
| Depreciation | |||||
| Non-Cash Items | 14.6 | 19.5 | 19.4 | 21.4 | -7.01 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.02 | 4.98 | 10.7 | 2.31 | -5.72 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -66.3 | -82.2 | -135 | -155 | -72 |
| Capital Expenditures | -0.316 | -0.445 | -0.139 | -0.02 | — |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.316 | -0.445 | -0.139 | -0.02 | — |
| Financing Cash Flow Items | — | — | -2.65 | -1.02 | -0.528 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 247 | 102 | 96.2 | 26.5 | 36.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 181 | 19.8 | -39.2 | -129 | -35.4 |